Pearl's PT001 meets COPD endpoint

Pearl Therapeutics Inc. (Redwood City, Calif.) said four doses of twice-daily PT001 met the primary endpoint in a Phase IIb trial to treat chronic obstructive pulmonary disease (COPD). PT001 significa...